Cargando…

Book Review: Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer

Detalles Bibliográficos
Autores principales:	Dhakal, Dipesh, Dhakal, Yogesh, Sohng, Jae K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660960/ http://dx.doi.org/10.3389/fphar.2017.00771

Ejemplares similares

Coalition of Biology and Chemistry for Ameliorating Antimicrobial Drug Discovery
por: Dhakal, Dipesh, et al.
Publicado: (2017)

Commentary: Toward a new focus in antibiotic and drug discovery from the Streptomyces arsenal
por: Dhakal, Dipesh, et al.
Publicado: (2015)

An Insight into the “-Omics” Based Engineering of Streptomycetes for Secondary Metabolite Overproduction
por: Chaudhary, Amit Kumar, et al.
Publicado: (2013)

Engineering actinomycetes for biosynthesis of macrolactone polyketides
por: Dhakal, Dipesh, et al.
Publicado: (2019)

Marine Rare Actinobacteria: Isolation, Characterization, and Strategies for Harnessing Bioactive Compounds
por: Dhakal, Dipesh, et al.
Publicado: (2017)

Editorial: Recent Advances in Application of Synthetic Biology for Production of Bioactive Compounds
por: Chu, Luan Luong, et al.
Publicado: (2021)

Microbial Biosynthesis of Chrysazin Derivatives in Recombinant Escherichia coli and Their Biological Activities
por: Poudel, Purna Bahadur, et al.
Publicado: (2022)

Glutathione S-conjugates as prodrugs to target drug-resistant tumors
por: Ramsay, Emma E., et al.
Publicado: (2014)

Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance
por: Evans, Nick, et al.
Publicado: (2022)

Complete Genome Sequence of Nocardia sp. Strain CS682, a Producer of Antibacterial Compound Nargenicin A1
por: Dhakal, Dipesh, et al.
Publicado: (2019)

A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
por: Riccardi, Federico, et al.
Publicado: (2023)

Novel Nargenicin A1 Analog Inhibits Angiogenesis by Downregulating the Endothelial VEGF/VEGFR2 Signaling and Tumoral HIF-1α/VEGF Pathway
por: Han, Jang Mi, et al.
Publicado: (2020)

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
por: Lashari, Bilal H., et al.
Publicado: (2018)

Recent Advances in Exploration and Biotechnological Production of Bioactive Compounds in Three Cyanobacterial Genera: Nostoc, Lyngbya, and Microcystis
por: Thuan, Nguyen Huy, et al.
Publicado: (2019)

Recent Advances in Strategies for Activation and Discovery/Characterization of Cryptic Biosynthetic Gene Clusters in Streptomyces
por: Nguyen, Chung Thanh, et al.
Publicado: (2020)

Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
por: Feng, Jianwei, et al.
Publicado: (2022)

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study
por: Qi, Xiangjun, et al.
Publicado: (2022)

Do antibody–drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study
por: Xia, Shuang, et al.
Publicado: (2022)

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

Metabolic Engineering of Escherichia coli for Enhanced Production of Naringenin 7-Sulfate and Its Biological Activities
por: Chu, Luan L., et al.
Publicado: (2018)

A review of recent advances on single use of antibody-drug conjugates or combination with tumor immunology therapy for gynecologic cancer
por: Wang, An-Jin, et al.
Publicado: (2022)

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
por: Jeong, Jae Ho, et al.
Publicado: (2022)

Linker Design Impacts Antibody-Drug Conjugate Pharmacokinetics and Efficacy via Modulating the Stability and Payload Release Efficiency
por: Su, Dian, et al.
Publicado: (2021)

Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development
por: Biber, Knut, et al.
Publicado: (2019)

Antibody-drug conjugates: the clinical development in gastric cancer
por: Zhu, Yingze, et al.
Publicado: (2023)

Production of a Novel Tetrahydroxynaphthalene (THN) Derivative from Nocardia sp. CS682 by Metabolic Engineering and Its Bioactivities
por: Mishra, Ravindra, et al.
Publicado: (2019)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022)

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

MicroRNA as an Important Target for Anticancer Drug Development
por: Fu, Zhiwen, et al.
Publicado: (2021)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules?
por: Nessler, Ian, et al.
Publicado: (2018)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

Challenges for Clinical Drug Development in Pulmonary Fibrosis
por: White, Eric S., et al.
Publicado: (2022)

Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy
por: Löscher, Wolfgang
Publicado: (2021)

A multifunctional drug consisting of tetracycline conjugated with odanacatib for efficient periodontitis therapy
por: Li, Dengke, et al.
Publicado: (2022)

Editorial: Drug Development and Target Discovery in Pulmonary Vascular Diseases
por: Zhang, Rui, et al.
Publicado: (2020)

Drugs and Targets in Fibrosis
por: Li, Xiaoyi, et al.
Publicado: (2017)

New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
por: Ni, Xiayun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bs8ehl50a0rb0lg5lu2gcii4u2